September 19th 2024
"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP.
September 16th 2024
Talazoparib emerging as new PARP inhibitor option in prostate cancer
August 19th 2021Results from the phase 2 TALAPRO-1 study published in the Lancet Oncology show favorable antitumor activity with talazoparib in heavily pretreated patients with metastatic castration-resistant prostate cancer and DDR-HRR gene alterations.
Novel blood test enhances prostate cancer screening
August 18th 2021Combining the Stockholm3 blood test with MRI-guided prostate biopsy reduced the number of MRIs performed and lowered overdetection, while not sacrificing the capacity to identify clinically significant tumors, according to findings from the STHLM3-MRI study.
Postprostatectomy radiation dose and timing affect quality of life
August 16th 2021"It is apparent from the results of these 2 studies that neither the higher-dose RT nor early RT after RP provide sufficient oncological benefits to justify the adverse impact on functional outcomes and HRQOL," writes Badar M. Mian, MD.
Final FDA blueprint available for MFS end point in nonmetastatic CRPC trials
August 13th 2021The FDA has officially released its finalized recommendation for the use of metastases-free survival as an end point in clinical trials evaluating treatments for patients with nonmetastatic castration-resistant prostate cancer.
Dr. Ketan K. Badani on how genomic tests help facilitate patient discussions
August 10th 2021“One of the toughest parts about having a discussion with a patient about low-risk or early-stage prostate cancer…is actually deciding what might be best for that individual patient,” says Ketan K. Badani, MD.
Dr. Abida on using PARP inhibitors in mCRPC patients with non-BRCA1/2 HRR gene alterations
August 2nd 2021Wassim Abida, MD, PhD, discusses whether he would recommend PARP inhibitors in patients with metastatic castration-resistant prostate cancer harboring alterations in homologous recombination repair genes other than BRCA1/2.
Dr. Kang discusses what a recent study of prostate MRI means for clinicians and patients
August 2nd 2021“While many patients may think of imaging tests, as many other tests, as [having] a binary outcome, it may be important to have a discussion about how the scoring and MRI works, [and] what the patient can expect to see on their report,” says Stella K. Kang, MD.
Real-world data show clinical utility of novel genomic test in early-stage prostate cancer
July 30th 2021Decipher Prostate Biopsy, a 22-gene microarray-based genomic classifier, showed potential as a tool to help guide decisions between active surveillance and radical treatment in men with localized prostate cancer.
Study supports use of androgen receptor inhibitors in older men with nmCRPC
July 26th 2021Researchers from the FDA’s Center for Drug Evaluation and Research determined that the benefits of androgen receptor inhibitors outweighed the risks in men aged ≥80 years with nonmetastatic castration-resistant prostate cancer.
Dr. Sereti on novel agent NOV202 plus olaparib in prostate cancer
July 20th 2021Evangelia Sereti, MSc, PhD, discusses the design/methodology and results of a preclinical study exploring the combination of the PARP inhibitor olaparib plus the novel agent NOV202 in BRCA1/2-mutated prostate cancer cells.